Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Rie
Contact Rie, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
BAP1 Loss Might Be a Predictive Biomarker for Immunotherapy Response in Pleural Mesothelioma
BAP1 BRCA1-associated protein 1 CR complete response DCR disease control rate ECOG Eastern Cooperative Oncology Group ICI immune checkpoint inhibitor IHC immunohistochemistry mRECIST modified response evaluation criteria in solid tumors OS overall survival PD progressive disease PFS Progression free survival PM pleural mesothelioma PR partial response PS performance status PS-L1 programmed death-ligand 1 RR response rate SD stable disease 1 Introduction Pleural mesothelioma (PM) is a rare and...
Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report
SMARCA4-deficient thoracic sarcoma is a rare tumor typically presenting as a mediastinal mass. The prognosis is estimated to be poor, and no effective treatment has been established. We present a case of a 76-year-old man who was diagnosed with SMARCA4-deficient thoracic sarcoma. The provisional diagnosis was carcinoma of unknown primary but subsequently corrected to SMARCA4-deficient thoracic sarcoma based on the panel-based cancer gene screening and immunohistochemistry.
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Rie
Contact Rie, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack